New drug DF5112 put to the test in healthy volunteers

This early-stage study tests a new drug, DF5112, in 48 healthy adults to see if it is safe and how the body handles it. Participants receive a single dose of the drug or a placebo and are monitored for about a week in a clinic, with follow-up visits for a month. The goal is to gather information on side effects, drug levels in the blood, and immune reactions.